Page last updated: 2024-12-11

rosiglitazone-metformin combination

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

rosiglitazone-metformin combination: a combination of metformin and rosiglitazone used for treating type 2 diabetes [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6445783
MeSH IDM0491270

Synonyms (8)

Synonym
rosiglitazone / metformin
metformin hydrochloride mixt. with rosiglitazone maleate
622402-70-4
rosiglitazone maleate and metformin hydrochloride
imidodicarbonimidic diamide, n,n-dimethyl-, monohydrochloride, mixt with 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione (2z)-2-butenedioate (1:1)
rosiglitazone maleate mixt. with metformin hydrochloride
rosiglitazone-metformin combination
(z)-but-2-enedioic acid;3-(diaminomethylidene)-1,1-dimethylguanidine;5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione;hydrochloride

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The TODAY clinical trial assessed severe adverse events (SAEs) and targeted nonsevere adverse events (AEs) before and after treatment failure, which was the primary outcome (PO)."( Safety and tolerability of the treatment of youth-onset type 2 diabetes: the TODAY experience.
, 2013
)
0.39
"The TODAY study represents extensive experience managing type 2 diabetes in youth and found that the three treatment approaches were generally safe and well tolerated."( Safety and tolerability of the treatment of youth-onset type 2 diabetes: the TODAY experience.
, 2013
)
0.39
" Overall adverse event (AE) rates and serious AE rates were similar between groups."( Efficacy and safety of avandamet or uptitrated metformin treatment in patients with type 2 diabetes inadequately controlled with metformin alone: a multicenter, randomized, controlled trial.
Cai, XL; Chen, YL; Gu, W; Hong, TP; Ji, LN; Li, CJ; Qiu, MC; Shan, ZY; Tian, HM; Xue, YM; Yang, HZ; Yang, JK; Zhao, JJ, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's14 (45.16)29.6817
2010's16 (51.61)24.3611
2020's1 (3.23)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.69 (24.57)
Research Supply Index3.87 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials14 (42.42%)5.53%
Reviews2 (6.06%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (51.52%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]